254 related articles for article (PubMed ID: 35757470)
1. Rab22a Promotes Epithelial-Mesenchymal Transition in Papillary Thyroid Carcinoma by Activating PI3K/AKT/mTOR Signaling Pathway.
Luo X; Wang J; Lu J; Wang X; Miao Y; Li Q; Li X; Wang L
Biomed Res Int; 2022; 2022():1874550. PubMed ID: 35757470
[TBL] [Abstract][Full Text] [Related]
2. Rab22a promotes the proliferation, migration, and invasion of lung adenocarcinoma via up-regulating PI3K/Akt/mTOR signaling pathway.
Wang J; Luo X; Lu J; Wang X; Miao Y; Li Q; Wang L
Exp Cell Res; 2022 Jul; 416(2):113179. PubMed ID: 35487271
[TBL] [Abstract][Full Text] [Related]
3. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
[TBL] [Abstract][Full Text] [Related]
4. Combretastatin A4 Regulates Proliferation, Migration, Invasion, and Apoptosis of Thyroid Cancer Cells via PI3K/Akt Signaling Pathway.
Liang W; Lai Y; Zhu M; Huang S; Feng W; Gu X
Med Sci Monit; 2016 Dec; 22():4911-4917. PubMed ID: 27966519
[TBL] [Abstract][Full Text] [Related]
5. CircNDST1 promotes papillary thyroid cancer progression via its interaction with CSNK2A1 to activate the PI3K-Akt pathway and epithelial-mesenchymal transition.
Shu C; Wang S; Hu J; Xu M; Deng H; Maimaiti Y; Huang T
J Endocrinol Invest; 2023 Mar; 46(3):545-557. PubMed ID: 36306106
[TBL] [Abstract][Full Text] [Related]
6. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
7. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
Zheng Y; Xie L; Xu S; Yan W; Zhang H; Meng Y; Liu J; Wei X
Mol Cell Biochem; 2021 Nov; 476(11):4031-4044. PubMed ID: 34244973
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
9. Effecacy of Biejia (Carapax Trionycis) and Ezhu (Rhizoma Curcumae Phaeocaulis) couplet medicine on epithelial-mesenchymal transition, invasion and migration of MDA-MB-231 triple negative breast cancer cells via PI3K/Akt/mTOR signaling pathway.
Zhu MJ; Xie S; Xie Q; Zhu JL; Huang YZ
J Tradit Chin Med; 2021 Dec; 41(6):853-861. PubMed ID: 34939381
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
Bian P; Hu W; Liu C; Li L
Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
[TBL] [Abstract][Full Text] [Related]
11. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.
Zheng J; Liu C; Shi J; Wen K; Wang X
Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidic Acid Receptor 5 (LPAR5) Plays a Significance Role in Papillary Thyroid Cancer via Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin (mTOR) Pathway.
Wu CY; Zheng C; Xia EJ; Quan RD; Hu J; Zhang XH; Hao RT
Med Sci Monit; 2020 Jan; 26():e919820. PubMed ID: 31902939
[TBL] [Abstract][Full Text] [Related]
13. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
[TBL] [Abstract][Full Text] [Related]
14. LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway.
Sun W; Qian K; Guo K; Chen L; Xiang J; Li D; Wu Y; Ji Q; Sun T; Wang Z
Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):382-389. PubMed ID: 32227107
[TBL] [Abstract][Full Text] [Related]
15. Daidzin targets epithelial-to-mesenchymal transition process by attenuating manganese superoxide dismutase expression and PI3K/Akt/mTOR activation in tumor cells.
Yang MH; Jung SH; Um JY; Kumar AP; Sethi G; Ahn KS
Life Sci; 2022 Apr; 295():120395. PubMed ID: 35181309
[TBL] [Abstract][Full Text] [Related]
16. Circ_100395 impedes malignancy and glycolysis in papillary thyroid cancer: Involvement of PI3K/AKT/mTOR signaling pathway.
Chen L; Zhuo D; Yuan H
Immunol Lett; 2022 Jun; 246():10-17. PubMed ID: 35447227
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
[TBL] [Abstract][Full Text] [Related]
18. Bicarbonate transporter SLC4A7 promotes EMT and metastasis of HNSCC by activating the PI3K/AKT/mTOR signaling pathway.
Hu J; Li G; Liu Z; Ma H; Yuan W; Lu Z; Zhang D; Ling H; Zhang F; Liu Y; Liu C; Qiu Y
Mol Carcinog; 2023 May; 62(5):628-640. PubMed ID: 36727616
[TBL] [Abstract][Full Text] [Related]
19. HPIP promotes thyroid cancer cell growth, migration and EMT through activating PI3K/AKT signaling pathway.
Wang SC; Chai DS; Chen CB; Wang ZY; Wang L
Biomed Pharmacother; 2015 Oct; 75():33-9. PubMed ID: 26463629
[TBL] [Abstract][Full Text] [Related]
20. Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells in Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway.
Li C; Zhou Y; Cai Y; Shui C; Liu W; Wang X; Jiang J; Zeng D; Gui C; Sun R
Med Sci Monit; 2019 Jul; 25():5054-5061. PubMed ID: 31322140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
